Incendia Therapeutics is discovering and developing novel anti-cancer medicines that are designed to reprogram the tumor microenvironment. Many cancers create immune exclusion barriers that prevent the immune system from attacking tumors. The Parthenon approach to overcoming these barriers is to modulate the interplay among cancer cells, stromal cells, and immune cells. Our lead program, PRTH-101, is a first-in-class humanized monoclonal antibody that blocks the interaction of Discoidin Domain Receptor 1 (DDR1) with collagen, thereby “punching holes” in the extracellular matrix barrier created by the tumor. With the extracellular matrix barrier breached, immune cells are able to infiltrate and attack the tumor. PRTH-101 is poised to enter Phase 1 clinical trials. PRTH-101 is followed by a pipeline of preclinical projects targeting orthogonal components of the tumor microenvironment that promote immune exclusion. Incendia combines its drug discovery and development efforts with a precision oncology approach to get the right medicines to the right patients. We use proprietary AI technology to digitally deconstruct the TME and develop unique insights to enable biomarker-driven patient selection strategies designed to guide clinical applications.
External link for Incendia Therapeutics
40 Guest St
Boston, Massachusetts 02135, US
Welcome to Incendia Therapeutics our new Senior Accountant, Salma Clark, MBA !!
I’m happy to share that I’m starting a new position as Senior Accountant at Incendia Therapeutics!
This content isn’t available here
Access this content and more in the LinkedIn app
Congratulations to Wendye Robbins as we celebrate her 1 year anniversary as President and CEO of Incendia Therapeutics. Thank you for all that you've done for us and looking forward to discoveries ahead! #workmilestone
This content isn’t available here
Access this content and more in the LinkedIn app
Incendia Therapeutics reposted this
Big week of conferences in Boston! Had a great time at Spatial Biology East engaging on tools and applications of spatial biology in oncology and beyond. It was a pleasure to present Incendia Therapeutics’ work on how we’re spatial biology in 2D and 3D to understand the complexities of immune phenotypes for target discovery and patient stratification. And a privilege to participate in an (all female!) panel on Spatial Omics in Pharma where we highlighted the promise and challenges of using spatial biology and bioinformatics to drive drug development. - with Xinwei Sher and Fredrick Gootkind #SpatialBiology #TME #PrecisionOncology #OncologyResearch #BreakingBarriers
Incendia Therapeutics reposted this
Incendia Therapeutics team members took a break from finding cures in the lab to attend a workshop on arranging flowers on Friday.
Incendia Therapeutics team members took a break from finding cures in the lab to attend a workshop on arranging flowers on Friday.
So exciting to share our work on immune phenotyping from H&E images and the association between immune exclusion and lack of response to checkpoint inhibitors in lung cancer at #ASCO24! - with G. Travis Clifton, Bahar Rahsepar, PhD, Matthew Bronnimann, Incendia Therapeutics, PathAI https://lnkd.in/ejGzFMzT #TME #ImmuneExclusion #HEbiomarkers #AI #PrecisionOncology
Looking forward to a great #ASCO24 where we will present our poster (Abstract 8539) with PathAI on how H&E-derived immune phenotypes relate to checkpoint inhibitor response in #NSCLC. This important work helps further Incendia Therapeutics' mission of targeting #ImmuneExclusion in cancer. #AI #TME #PrecisionOncology #BreakingBarriers
This week at #ASCO2024 we will be presenting two posters focused on applying AI-powered pathology for #cancerresearch. Read more about the abstracts and add the posters to your program. 𝘑𝘶𝘯𝘦 2𝘯𝘥, 2024 - 9:00 𝘈𝘔 - 12:00 𝘗𝘔 𝗔𝗯𝘀𝘁𝗿𝗮𝗰𝘁 𝟰𝟱𝟭𝟵: 𝗔𝘀𝘀𝗼𝗰𝗶𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗺𝗮𝗰𝗵𝗶𝗻𝗲 𝗹𝗲𝗮𝗿𝗻𝗶𝗻𝗴 (𝗠𝗟)–𝗱𝗲𝗿𝗶𝘃𝗲𝗱 𝗵𝗶𝘀𝘁𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗳𝗲𝗮𝘁𝘂𝗿𝗲𝘀 𝘄𝗶𝘁𝗵 𝘁𝗿𝗮𝗻𝘀𝗰𝗿𝗶𝗽𝘁𝗼𝗺𝗶𝗰 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝘀𝘂𝗯𝘁𝘆𝗽𝗲𝘀 𝗶𝗻 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗿𝗲𝗻𝗮𝗹 𝗰𝗲𝗹𝗹 𝗰𝗮𝗿𝗰𝗶𝗻𝗼𝗺𝗮 (𝗥𝗖𝗖) Presented by: Shima Nofallah Previously, transcriptomic analysis in the Phase 3 IMmotion 151 (Im151) trial identified 7 molecular subtypes that showed differential outcomes to Atezolizumab+Bevacizumab (A+B) vs Sunitinib (S) treatment. In this abstract, in collaboration with Genentech, human interpretable features (HIFs), including blood vessels, immune cells, fibroblasts, tissue morphologies, and nucleus shape, extracted from H&E-stained whole slide images (WSI) from Im151 and Im150, were used to identify positively associated HIFs within each subgroup in the Im151 WSI and then validated in Im150 molecular subgroups. 169 HIFs were differentially enriched across 3 molecular subsets in both datasets. Our results suggest that clinically relevant RCC subtypes may be extracted directly from H&E-stained WSI and may complement gene expression-based patient stratification and selection strategies. Add to your schedule: https://lnkd.in/eK4sSdxw 𝘑𝘶𝘯𝘦 3𝘳𝘥, 2024 - 1:30 𝘗𝘔 - 4:30 𝘗𝘔 𝗔𝗯𝘀𝘁𝗿𝗮𝗰𝘁 𝟴𝟱𝟯𝟵: 𝗖𝗼𝗿𝗿𝗲𝗹𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗶𝗺𝗺𝘂𝗻𝗲 𝗽𝗵𝗲𝗻𝗼𝘁𝘆𝗽𝗲𝘀 𝗱𝗲𝗿𝗶𝘃𝗲𝗱 𝗳𝗿𝗼𝗺 𝗛&𝗘-𝘀𝘁𝗮𝗶𝗻𝗲𝗱 𝘄𝗵𝗼𝗹𝗲 𝘀𝗹𝗶𝗱𝗲 𝗶𝗺𝗮𝗴𝗲𝘀 𝘄𝗶𝘁𝗵 𝗽𝗿𝗼𝗴𝗻𝗼𝘀𝗶𝘀 𝗮𝗻𝗱 𝗿𝗲𝘀𝗽𝗼𝗻𝘀𝗲 𝘁𝗼 𝗰𝗵𝗲𝗰𝗸𝗽𝗼𝗶𝗻𝘁 𝗶𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀 𝗶𝗻 𝗡𝗦𝗖𝗟𝗖 Presented by: Bahar Rahsepar, PhD The classification of tumors as inflamed, excluded or desert based on spatial patterns of tumor infiltrating lymphocytes (TILs) is a potential biomarker of patients likely to respond to checkpoint inhibitors (CPI). In this abstract, in collaboration with Incendia Therapeutics, PathExplore IOP is used to classify immune-phenotype (IP) based on patch level TIL distribution in tumor core and periphery from H&E images. Survival analysis indicates Immune inflamed phenotype is associated with improved PFS in CPI-treated NSCLC patients independent of PD-L1 status. Add to your schedule: https://lnkd.in/eUZvYYzw #pathology #biotech #AI #digitalpathology #oncology #biotechnology #ASCO #ASCO24
Incendia Therapeutics reposted this
Heading to ASCO this week? Be sure to visit Incendia Therapeutics' poster highlighting how AI models can improve NSCLC patient outcomes! 𝐑𝐞𝐥𝐞𝐚𝐬𝐞 𝐚𝐭 𝐚 𝐆𝐥𝐚𝐧𝐜𝐞: 🖥 In collaboration with PathAI, the team at Incendia Therapeutics have identified digital biomarkers that predict progression free survival (PFS) in a CPI- treated clinical NSCLC cohort. 📊 Their data demonstrate a clear correlation between immune phenotypes and survival following checkpoint inhibitor therapy in NSCLC 🏥 These digital pathology-based biomarkers are independent of PD-L1 status, providing a new potential avenue to assess treatment benefits. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐧𝐞𝐰𝐬 𝐫𝐞𝐥𝐞𝐚𝐬𝐞: https://lnkd.in/dNJrp_gd #ASCO2024 #Oncology #Pathology #PrecisionMedicine #CancerResearch #CheckpointInhibitors #NSCLC #DigitalPathology American Society of Clinical Oncology (ASCO)